Loading…
Green Valley Fertility Partners failed to adequately test reproductive donors for communicable diseases as required under federal regulations for human cells and tissues (HCT/Ps), specifically missing West Nile Virus (WNV) nucleic acid testing during the required June-October screening periods. The company marked donors as "eligible" without documented test results for WNV NAT, including at least one donor from whom oocytes were recovered in June 2024. This was a repeat violation—the same testing deficiency had been previously cited during an FDA inspection in April 2022—demonstrating the company's failure to correct known compliance gaps.